Responses
Original articles
Inflammatory bowel disease
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Compose a Response to This Article
Other responses
No responses have been published for this article.